2018 Diagnose Diagnostic Imaging Disease 
Imaging Technology
OCTOBER 5, 2023
Specifically, this sub-group examined the performance of flotufolastat F 18 PET in newly diagnosed, high-risk prostate cancer patients who had negative results with conventional imaging. Kuo, MD, Ph.D. , Departments of Medical Imaging, Medicine, and Biomedical Engineering. Recently approved by the U.S. on behalf of Gary A.
Vesta Teleradiology
FEBRUARY 3, 2024
Like the general populace, prevalent causes of mortality within Native American communities encompass heart disease, cancer, and accidents. By partnering with us, Indian Health Services can confidently meet the demands of patient care, ensuring every individual receives the prompt and precise diagnoses they deserve.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Imaging Technology
MAY 30, 2023
It represents a new class of purposely engineered, high-affinity PSMA-targeted radiopharmaceuticals based on novel radiohybrid technology, which may offer diagnostic imaging and therapeutic potential. POSLUMA was developed to assist physicians in the detection and localization of prostate cancer. POSLUMA was approved by the U.S.
AuntMinnie
MARCH 26, 2024
Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7
Imaging Technology
JULY 28, 2023
“The addition of POSLUMA to the highly respected NCCN Guidelines is a major milestone for Blue Earth Diagnostics,” said David E. We believe it further validates the clinical utility of POSLUMA in patients with newly diagnosed or recurrent prostate cancer, and can help expand patient access. Blue Earth Diagnostics received U.S.
AuntMinnie
JUNE 20, 2024
Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. Lutathera was approved for adults by the FDA in 2018 after the therapy resulted in progression-free survival (median overall survival of 11.7
Global Radiology CME
JULY 26, 2021
Porencephaly is readily diagnosed via imaging. Avery’s Diseases of the Newborn, Elsevier, 2018, pp. Obstetric Imaging: Fetal Diagnosis and Care, Elsevier, 2018, pp. Diagnostic Imaging: Obstetrics, Elsevier, 2016, pp. Seeing the radiographic images made medical education come to life for him.
Expert insights. Personalized for you.
52 
Let's personalize your content